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Abstract: Using three surveys, a comparative assessment of needle performance and patient 
preference for 27-gauge (G) and 29G needles for glatiramer acetate administration for multiple 
sclerosis therapy was performed. Eligible patients participated in a specialty pharmacy program 
and administered glatiramer acetate for 1 month. In Survey 1 on the 27G needle, 545 (82.70%) 
patients reported no needle problems, 106 (16.09%) cited one type (dull, bent, or broken), five 
(0.76%) cited two types, and three (0.46%) cited all three types. In Survey 2 on the 29G needle, 
553 (98.05%) indicated no problems, two (0.35%) cited dull needles, and nine (1.60%) cited 
bent needles. On the 29G needles versus 27G needles pain comparison, 219 (38.83%) reported 
the 29G needle was a little better, and 155 (27.48%) reported it was a lot better than the 27G. 
For injection-site experiences, 515 patients (91.31%) reported no, very slight, or mild reactions 
with the 29G needle. In Survey 3, over 76% of patients preferred the 29G to the 27G needle and 
significantly fewer patients reported one or more problems with the 29G needle compared to 
patients reporting problems with the 27G needle (P  0.00001). In conclusion, significantly fewer 
patients reported problems after 30 days of use of the 29G than the 27G needle. Fewer injection-
site experiences occurred with the 29G needle and the 29G needle was preferred overall.
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Introduction
Glatiramer acetate (Copaxone®, 20 mg; Teva Pharmaceuticals, Inc., Kansas City, MO, 
USA) is approved for the treatment of clinically isolated syndrome (CIS) and relapsing 
remitting multiple sclerosis (RRMS).1,2 Glatiramer acetate is believed to reduce both 
the inflammation and neurodegeneration occurring in the pathophysiology of multiple 
sclerosis by a variety of mechanisms, but it is primarily regarded as a T-cell-directed 
immunotherapeutic agent.3–5
Disease-modifying drugs (DMDs) for multiple sclerosis (MS) retard progression 
by reducing the incidence of relapses and magnetic resonance imaging (MRI) activity 
associated with the underlying pathology of the disease.6 However, all currently avail-
able DMDs for MS are delivered by injection. Injection-site experiences or reactions 
(ISEs) characterized by pain, swelling, redness, or inflammation have been experienced 
by patients who self-inject glatiramer acetate, interferon beta-1b, or interferon beta-1a.7 
Indeed, ISEs are the single most common side effect of glatiramer acetate.7 Although 
these experiences are typically not serious, they can be uncomfortable and weaken 
a patient’s commitment to continuing treatment. Furthermore, compliance with, and 
acceptance of, a DMD with proven effectiveness is influenced by a patient’s perception 
of the pain caused by drug delivery. Also, pain perception is more enhanced in females Drug, Healthcare and Patient Safety 2009:1 82
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than in males, coincident with the increased prevalence of 
MS in woman over men.8,9
Injection needles are characterized by their gauge (G), 
which reflects the diameter of the cannula. The higher the 
gauge, the thinner the needle. With the improvements of 
the 29G needle geometry, the outer diameter is reduced but the 
inner diameter of the lumen remains the same so that the same 
functionality is maintained with respect to flow rate, and speed 
of injection as well as the force applied on the syringe and 
drug solution.10 With some needles, an increase in the needle 
gauge, or thinness, may be associated with an increase in 
bending or breakage. Thus, improving the design of the needle 
to reduce injection pain and site experiences without compro-
mising the needle’s performance is an important improvement 
in the ongoing management of MS using glatiramer acetate. 
Improvements such as these are likely to enhance patient 
adherence to the drug administration regimen.
A thinner 29G needle was expected to reduce injection 
pain, injection site experiences, and be more preferred relative 
to a 27G needle. Accordingly, three surveys were conducted 
to determine if the 29G needle was, indeed, an improvement 
over the previous 27G needle in terms of pain, ISEs and 
patient preference. The primary objective of the surveys was 
to provide a comparative assessment of patient-reported gross 
needle performance such as bending, dullness, or breaking 
between a 27G and 29G needle after 30 days of use. Another 
objective was a comparative assessment between the two 
needles in terms of overall patient preference.
Methods
Patients
Patients with MS who were registered in a specialty pharmacy 
program and used glatiramer acetate 27G prefilled syringe 
(PFS) for a minimum of one month  prior to study entry. Patient 
participation in the study was approximately 30 days.
Study injection system
A PFS consisting of a 1 mL Hypack Physiolis syringe barrel 
(Becton Dickinson, Franklin Lakes, NJ, USA) fitted with a 
29G/5 bevel/0.5 inch needle with a thermoplastic elastometer 
(TPE) shield (Hypak Physiolis syringe, Becton Dickinson). 
Patients were advised that they could continue using the 
autoinject 2 device (Owen Mumford Ltd., Woodstock, UK) 
or manually inject as they see fit.
Study design
This was a nonrandomized, unblinded, patient reported, com-
parative assessment of needle performance and preference.
Surveys
Patients with MS who had been using the 27G needle to 
administer 20 mg of glatiramer acetate daily were interviewed 
in three separate surveys to determine if injections with the 
29G needle were associated with reduced pain, fewer ISEs 
and were more preferred. Three telephone surveys were 
administered over 30 days.
First telephone survey
The survey was administered by a specialty pharmacy health 
care professional (HCP) who obtained verbal informed 
consent from the patient. The first survey consisted of 
a needle performance question on the 27G needle. The 
needle performance question consisted of asking the 
patient whether they had experienced in the last 30 days a 
needle issue which may have included the needle feeling 
dull or the needle bending during injection. Through the 
usual BioScrip refill procedure, a 30-day supply of the 
new glatiramer acetate 29G PFS was sent to the patient 
and a 7–10-day post-drug-shipment call with the patient 
was scheduled.
Second telephone survey
The second survey was a 7–10-day post-drug-shipment call 
administered by a HCP. Survey 2 consisted of: 1) Qualifying 
questions to ensure patients had started using the 29G needle; 
2) Questions on whether they had experienced pain with the 
29G needle and how they would rate it on a 5-point scale 
from 0 (no pain at all) to 4 (severe pain) and how would they 
compared it to pain they had experienced in the past with 
the 27G needle on a 5-point scale from +2 (a lot better than 
your usual experience) to -2 (a lot worse than your usual 
experience); 3) Questions on whether they had experienced 
ISEs and how they would rate them on a scale from 0 (no site 
reactions at all) to 4 (severe site reactions) and how they 
would compared them to the ISEs they had experienced in the 
past with the 27G needle using a scale from +2 (a lot better 
than your usual experience) to -2 (a lot worse than your usual 
experience); and 4) A needle performance question on the 
29G needle, asking whether there were needle issues such 
as it felt dull or possible bending, similar to the question in 
Survey 1 concerning the 27G needle.
Third telephone survey
The third survey was administered by a HCP approxi-
mately 30 days after the 1st survey. Survey 3 consisted of: 
1) A needle performance question regarding the 29G needle 
on whether there were needle issues in the last 30 days, Drug, Healthcare and Patient Safety 2009:1 83
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such as being dull or bent; and 2) An overall preference 
question consisting of asking the patient whether they 
preferred the new needle to their past experience with the 
27G needles.
Statistical analyses
The patient ratings for each of the surveys to the questions 
on pain, needle performance and needle preference were 
analyzed using descriptive statistics. Chi-squared analyses 
were used to determine whether there were differences in 
the proportion of patients reporting needle problems, and 
single-sample t-tests were used to compare the ratings means 
between the 27G and 29G needles for pain, ISEs, and patient 
preference.
Results
Survey 1
Six hundred seventy-two patients were contacted by the 
specialty pharmacy for participation in this study. Thirteen 
patients declined to participate. A total of 659 patients par-
ticipated in Survey 1, 564 in Survey 2, and 562 in Survey 3. 
Eighty-five percent of patients who began the study provided 
complete data on all three survey calls conducted by the 
specialty pharmacy program.
Demographic characteristics of patients who completed 
the study are shown in Table 1.
The majority of the survey participants were female 
(76.9%), whose average age was 48 years. Patients surveyed 
had MS for approximately 9.5 years, and were taking 
glatiramer acetate for an average of 45 months. With regard 
to 27G needle performance, of the 659 patients responding 
to the needle performance question, 545 (82.7%) indicated 
no problems, 106 (16.1%) reported one type of problem, 
five (0.8%) reported two types of problems, and three (0.5%) 
reported three types of problems (Figure 1).
Survey 2
Survey 2 was administered to 564 patients after they had 
been using the new 29G needles from four to 30 days 
(mean = 21.5, standard deviation [SD] = 5.8). The method 
used to self-inject for these 564 patients were as follows: 
356 (63.1%) used the autoinject device, 166 (29.3%) 
used manual injections, and 42 (7.4%) used both methods 
(Table 1). Concerning needle performance, 553 (98%) 
patients surveyed indicated no problems with 29G needle, 
two (0.35%) complained of needle dullness, and nine (1.6%) 
reported needles bending. There were no reports of needle 
breakage (Figure 1). The subjective pain ratings assigned by 
the 564 patients are shown in Table 2. The median pain rating 
for the 29G needle was 1.0, with a mean of 1.09 and SD of 
0.81. ISEs assigned by patients (n = 564) are presented in 
Table 3. The median ISE rating was 2, the mean was 1.35, 
and the SD was 0.94.
Pain with 29G needles compared to 27G needles
Table 4 shows the patient (n = 564) perceived pain 
comparison ratings between the 29G needle relative to 
past experiences with a 27G needle using a scale from 
Table 1 Patient demographic characteristics
Characteristic Mean SD Median Range
Age (years) 48.07 10.77 48 18–85
Age at diagnosis (years) 38.54 10.13 39 12–68
MS disease duration (years) 9.53 8.21 7 0–46
Length of time on GA 
(months)
45.16 38.46 40 0–340
Gender
  F: 432 (76.9%)
  M: 130 (23.1%)
Injection method
  Autoinjector: 355 (63.1%)
  Manual: 165 (29.4%)
  Both: 42 (7.5%)
No Problems 82.7%
Dull
12%
Bent
6%
Broken 0.8%
No Problems 98%
Dull 0.35% Bent 1.6%
27G 29G
Figure 1 needle performance data on 27G and 29G needles.
Table 2 Pain ratings assigned to an injection with a 29G needle 
(564 respondents)
Pain rating Number of patients Percent
0 – no pain at all 130 23.05
1 – very slight pain, hardly 
noticeable
283 50.18
2 – mild pain 121 21.45
3 – moderate pain 30 5.32
4 – severe pain 0 0Drug, Healthcare and Patient Safety 2009:1 84
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+2 (a lot better) to -2 (a lot worse). The median pain 
comparison rating was 1.0, with a mean of 0.89 and SD of 
0.86 (P  0.001).
iSes with 29G needles compared to the 27G
Table 4 shows the ISE comparison ratings that were assigned 
by patients (n = 564) to the 29G needle relative to past 
experience with the 27G needle using a subjective rating 
scale from +2 (a lot better) to -2 (a lot worse). Fewer ISEs 
with the 29G needle were reported by 49.2% of patients 
compared with the 27G needle used previously. The median 
ISEs comparison rating was 0, the mean was 0.6, and the SD 
was 0.8 (P  0.001).
Survey 3
Five hundred sixty-two patients were administered the 
third survey. All had continued to use the 29G needle since 
the last survey call. Concerning performance of the 29G 
needle, 558 (99.3%) patients indicated no problems, and 
four (0.7%) patients reported a problem with needle bending. 
There were no reports of difficulties with either dull needles 
or needles breaking. Concerning overall preference, over 
76% of patients preferred the 29G needle to the 27G needle 
(Figure 2).
Discussion
Based on three telephone surveys, significantly fewer 
MS patients reported problems in the preceding 30 days 
using a thinner 29G needle to administer glatiramer 
acetate than the 27G needle used previously for drug 
delivery. In fact, two-thirds of the patients had less injec-
tion pain with the 29G relative to the 27G needle. Almost 
half of the patients experienced fewer ISEs with the 29G 
needle and another 46% experienced no difference in ISEs 
between the 29G and 27G needles. When interpreting 
the results of the patient surveys, it should be noted that 
the surveys were unblinded and the results were based 
on subjective questionnaires. Patients were asked to rate 
their pain and ISEs using the 29G needle and compare 
it to their remembered experience with the 27G needle. 
Additionally, while patients had at least 30 days of expe-
rience with injections with the 27G needle prior to entry 
into the study, there is no comparator arm so it is possible 
that the decreasing pain and ISEs with the 29G needle 
may have been a function of time rather than the gauge 
of needle. Nevertheless, the consistency of the results 
from the three surveys suggest that the 29G needle is a 
significant improvement over the 27G needle used previ-
ously for glatiramer acetate administration. Since almost 
three quarters of patients surveyed preferred the 29G 
needle to the 27G needle, this needle improvement may 
result in improved patient adherence in glatiramer acetate 
administration.
Table 3 The iSe ratings assigned to 29G needle (564 respondents)
ISE rating Number of 
patients
Percent
0 – no site reaction at all 136 24.11
1 – very slight reaction, 
barely noticeable
144 25.53
2 – mild reaction 235 41.67
3 – moderate reaction 48 8.51
4 – severe reaction 1 0.18
Table 4 Pain and iSe comparison ratings assigned to an injection 
with a 29G needle in comparison to their experience with 27G 
needle (564 respondents)
Comparison 
rating
Pain comparisons 
Number of patients 
(%)
ISE comparisons 
Number of patients 
(%)
+2 – a lot better 155 (27.48) 94 (16.67)
+1 – a little better 219 (38.83) 183 (32.45)
0 – no difference 168 (29.79) 263 (46.63)
-1 – a little worse 20 (3.55) 21 (3.72)
-2 – a lot worse 2 (0.35) 3 (0.53)
29G needle a lot 
more 32.56% 29G needle 
a little more 
44.31%
No preference
18.7%
27G needle a lot more 1.1% 27G needle a little more 3.4%
Figure 2 Overall preference for 29G needle relative to the 27G needle.Drug, Healthcare and Patient Safety 2009:1 85
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Additional studies evaluating differences between the 
27G and 29G needles were recently reported by Jaber and 
colleagues.11 In this report, the results of two clinical trials 
with healthy volunteers and five surveys with MS patients 
comparing satisfaction with 29G/5-bevel needle with a TPE 
shield relative to the 27G/3-bevel needle with standard rubber 
shield for injection of interferon beta-1a were reviewed. 
The findings of this report indicate that the pain scores for 
the 29G/5-bevel needle with TPE shield decreased by 40% 
and skin penetration improved by 69% compared with the 
27G/3-bevel needle with standard rubber shield. Moreover, 
63% of MS patients surveyed thought that injections were 
less painful with the 29G/5-bevel needle than the 27G/3-bevel 
needle.11
The US Food and Drug Administration recently approved 
glatiramer acetate administration for patients who are in the 
early stages of their disease as well as patients diagnosed 
with RRMS. Early glatiramer acetate use has been shown 
to be an effective intervention, reducing MS relapse rates 
significantly.12 Indeed, patients are recommended to start 
taking glatiramer acetate once they have experienced their 
first clinical episode and have MRI features that are consistent 
with MS, even if the symptoms presented are relatively mild.13 
Overall the side effects of glatiramer acetate are relatively 
limited and mild. However, the occurrence of ISEs can act 
as a deterrent for early and continued glatiramer acetate 
therapy. To facilitate good injection routines, patients start-
ing daily subcutaneous self-injections of glatiramer acetate 
receive training on injection-site preparation and injection 
technique.14
Despite attention to good injection practices, patients who 
inject glatiramer acetate using the 27G needles sometimes 
experience ISEs. Improving the design of existing needles to 
reduce injection-associated pain and ISEs without compro-
mising the needle’s functional integrity is important in the 
long-term management of MS. The results presented here 
indicate that the MS patients perceive that the 29G needle is 
a significant improvement over the 27G needle used previ-
ously for glatiramer acetate administration.
Conclusions
In this study, MS patients using the 29G needle for daily 
administration of glatiramer acetate reported significantly 
fewer problems relative to the 27G needle used previously. 
The parameters examined were pain, patient satisfaction, 
and needle performance issues such as dullness, bending 
or breaking. The increased satisfaction associated with 
the 29G needle is likely to increase compliance and thus 
enhance the positive effects of this DMD in curtailing MS 
progression.
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